Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medifast (MED) Accounts Payables (2016 - 2025)

Medifast (MED) has disclosed Accounts Payables for 16 consecutive years, with $38.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accounts Payables fell 32.1% year-over-year to $38.4 million, compared with a TTM value of $38.4 million through Dec 2025, down 32.1%, and an annual FY2025 reading of $38.4 million, down 32.1% over the prior year.
  • Accounts Payables was $38.4 million for Q4 2025 at Medifast, down from $41.2 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $174.4 million in Q1 2022 and bottomed at $38.4 million in Q4 2025.
  • Average Accounts Payables over 5 years is $103.2 million, with a median of $104.2 million recorded in 2023.
  • The sharpest move saw Accounts Payables surged 79.74% in 2021, then plummeted 41.78% in 2025.
  • Year by year, Accounts Payables stood at $163.3 million in 2021, then decreased by 17.52% to $134.7 million in 2022, then plummeted by 35.84% to $86.4 million in 2023, then tumbled by 34.62% to $56.5 million in 2024, then tumbled by 32.1% to $38.4 million in 2025.
  • Business Quant data shows Accounts Payables for MED at $38.4 million in Q4 2025, $41.2 million in Q3 2025, and $40.3 million in Q2 2025.